VIDEO: SER-109 may represent ‘paradigm shift’ in management of recurrent C. difficile

VIDEO: SER-109 may represent ‘paradigm shift’ in management of recurrent C. difficile

Jessica R. Allegretti, MD, MPH, spoke with Healio about a study demonstrating the efficacy of SER-109 in preventing recurrent Clostridioides difficile infection, including in patients using acid-suppressing medications.The data, presented at the ACG Annual Meeting, showed that SER-109 (Seres Therapeutics), an oral investigational microbiome therapeutic, reduced recurrent C. difficile infection across a broad range of risk factors.“SER-109 may represent a potential paradigm shift in clinical management of patients with recurrent C. difficile because we’re seeing some of these moreRead More

Share on facebook
Share on twitter
Share on linkedin